, cognitive, emotional, and social), 3 symptom subscales (fatigue, pain, nausea/vomiting), and 6 single-item scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The QLQ-C30 also generates a global health status based
Search Results
Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E. Pettersson, and Richard Sawatzky
Iulia Giuroiu and Diane Reidy-Lagunes
.gov identifier: NCT01010126). However, his treatment course was complicated by grade 3 mucositis, grade 2 thrombocytopenia, and grade 2 fatigue, which led to disenrollment from the trial in March 2010 despite a dose reduction. In August 2010, the patient again
Jun Gong, Chongkai Wang, Peter P. Lee, Peiguo Chu, and Marwan Fakih
decreased in size. Because of significant fatigue, the patient was transitioned to maintenance 5-FU, leucovorin, and bevacizumab starting from cycle 5. He received an additional 11 cycles of maintenance 5-FU, leucovorin, and bevacizumab (16 cycles overall
Ania Syrowatka, James A. Hanley, Daniala L. Weir, William G. Dixon, Ari N. Meguerditchian, and Robyn Tamblyn
depression. 6 Reasons range from significant overlaps in prodromal symptoms of psychological distress and treatment-related side effects (eg, insomnia and fatigue) to patients' reluctance to disclose psychological distress due to stigma around mental health
Emily H. Castellanos, Sheau-chiann Chen, Hillary Drexler, and Leora Horn
.79–0.94), adjusted for anticipated benefit and toxicity grades. For example, 32.5% of patients stated they would decline curative intent treatment if grade 2 vomiting were expected versus 10.6% if grade 2 rash were expected. Fatigue also had a strong impact on
Presenters: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff
(Figure 1). The patient elected to receive full-dose pazopanib. The dose was reduced from 800 mg/day to 600 mg/day due to fatigue. After 10 months, he developed progressive disease. Preferred subsequent therapy is cabozantinib, nivolumab monotherapy, or
Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp
particularly at risk for experiencing high symptom burden and loss of muscle. 16 – 18 Patients with muscle loss often require hospital-level care to address treatment adverse effects and high symptom burden (eg, pain, fatigue, nausea). 19 Notably
Melissa S.Y. Thong, Daniel Boakye, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt
Chemotherapy was associated with increased non–CRC-related MS visits in our study, probably because of long-term adverse treatment effects, such as neuropathy or fatigue. These symptoms can persist and have a negative impact on functioning. 43 , 44 Our results
Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Bruce Compas, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Paul B. Jacobsen, Sara J. Knight, Kate Learson, Michael H. Levy, Matthew J. Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, and Michael A. Zevon
, dramatic advances in early detection and treatment options have increased overall survival rates in patients of all ages with cancer. At the same time, these improved treatment options are also associated with substantial long-term side effects. Fatigue
included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0
